<DOC>
	<DOCNO>NCT01700751</DOCNO>
	<brief_summary>This pilot clinical trial study safety maximum tolerate dose brentuximab vedotin give tacrolimus methotrexate unrelated allogeneic donor stem cell transplant patient acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome . The addition brentuximab vedotin tacrolimus methotrexate may result significant reduction graft versus host disease patient .</brief_summary>
	<brief_title>Brentuximab Vedotin Prevention ( GVHD ) After Unrelated Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient must schedule undergo stem cell transplantation one follow diagnosis : acute myeloid leukemia ( AML ) CR1 ( first complete remission , CR CRi ) CR2 ( second complete remission , CR CRi ) , acute lymphoblastic leukemia ( ALL ) CR1 CR2 ( CR CRi ) myelodysplastic syndrome ( MDS ) without progression AML . Chronic myelogenous leukemia ( CML ) NonHodgkin 's lymphoma ( NHL ) Hodgkin 's disease ( HD ) Chronic lymphocytic leukemia ( CLL ) Multiple myeloma ( MM ) Patients must recipient unrelated donor peripheral blood stem cell product . Mismatches antigen allele level eligible . Match must 6 7 8 locus ( HLA A , B , C , DRB1 ) . Patient must receive one follow conditioning regimen : total body radiation ( single fractionate dose ) /cyclophosphamide , busulfan/ cyclophosphamide , fludarabine/busulfan/lymphocyte immune globulin ( ATGAM/thymo ) . Patient must ≥ 18 year ≤ 70 year age . Patient must ECOG performance status ≤ 2 Karnofsky performance scale ≥ 60 % Patient must CD34+ stem cell ≥ 2x106/kg ( actual body weight recipient ) available transplantation . Patient must appropriate organ function define ( criterion meet screen day first dose brentuximab vedotin ( assessed prior dose ) ) : Total bilirubin ≤ 2.0 x IULN AST ( SGOT ) /ALT ( SGPT ) ≤ 3.0 x IULN Serum creatinine ≤ 2.0 x IULN Estimated Creatinine Clearance &gt; 30 ml/min Cardiac ejection fraction &gt; 40 % DLCO/VA &gt; 40 % Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Patient must able understand willing sign IRB approve write informed consent document . Patient must prior exposure brentuximab vedotin . Patient must history malignancy remission least 3 year , exception basal nonmelanoma skin cancer treat local resection intraepithelial lesion carcinoma situ cervix prostate curatively treat . Patient must receive investigational agent . Patient must active CNS involvement . Patient must history allergic reaction attribute compound similar chemical biologic composition brentuximab vedotin agent use study . Patients must previous radiation therapy mediastinum lung . Patient must uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , active pulmonary disease , psychiatric illness/social situation would limit compliance study requirement ( criterion meet screening day prior first dose brentuximab vedotin ) . Patient must pregnant and/or breastfeed . Patient must know HIVpositive combination antiretroviral therapy . Patient must previous allogeneic syngeneic transplant . Prior autologous transplant allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>